Genmab Combination Improves Survival in Phase 3 Cancer Trial
Genmab reported positive Phase 3 results for petosemtamab plus Keytruda as first-line treatment for PD-L1-positive recurrent or metastatic head and neck cancer. The combination significantly improved overall survival.